These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22653574)

  • 21. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
    Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
    Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester.
    Christiansen M; Nørgaard-Pedersen B
    Clin Genet; 2005 Jul; 68(1):35-9. PubMed ID: 15952984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
    Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Down's syndrome screening strategies in Asians combining serum free beta-hCG and alpha-fetoprotein with maternal age.
    Hsu JJ; Hsieh TT; Soong YK; Spencer K
    Prenat Diagn; 1997 Aug; 17(8):707-16. PubMed ID: 9267893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
    Bestwick JP; Huttly WJ; Wald NJ
    J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A.
    Spencer K
    BJOG; 2001 Oct; 108(10):1043-6. PubMed ID: 11702835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.
    Spencer K; Aitken DA; Macri JN; Buchanan PD
    Prenat Diagn; 1996 Jul; 16(7):605-13. PubMed ID: 8843469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prenatal diagnostics during the first trimester in the clinical praxis].
    Calda P; Vísková H; Bezdícková D; Zima T
    Cas Lek Cesk; 2006; 145(7):575-7. PubMed ID: 16921789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of the integrated test in the Down's syndrome screening algorithm.
    Springer D; Loucky J; Tesner P; Cutka D; Stejskal D; Gregor V; Zima T
    J Med Screen; 2018 Sep; 25(3):114-118. PubMed ID: 29575979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy].
    Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM
    Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated serum screening for Down syndrome in primary obstetric practice.
    Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
    Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contingent screening for Down syndrome--results from the FaSTER trial.
    Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
    Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for Down's syndrome. The role of intact hCG and free subunit measurement.
    Spencer K
    Scand J Clin Lab Invest Suppl; 1993; 216():79-96. PubMed ID: 7690984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of combined, stepwise sequential, contingent, and integrated screening in 7292 high-risk pregnant women.
    Guanciali-Franchi P; Iezzi I; Palka C; Matarrelli B; Morizio E; Calabrese G; Benn P
    Prenat Diagn; 2011 Nov; 31(11):1077-81. PubMed ID: 21800336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.